Preventive effect of zelandopam, a dopamine D1 receptor agonist, on cisplatin-induced acute renal failure in rats

European Journal of Pharmacology

Volumn 461, Issue 2-3, 2003, Pages 191-195

  Yatsu, Takeyuki ^a   Aoki, Motonori ^a   Inagaki, Osamu ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Acute; Cisplatin; Dopamine D1 receptor; Renal failure; Zelandopam

Indexed keywords

4 (3,4 DIHYDROXYPHENYL) 1,2,3,4 TETRAHYDRO 7,8 DIHYDROXYISOQUINOLINE; ASCORBIC ACID 2 OCTADECYL ETHER; CISPLATIN; CREATININE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; ZELANDOPAM;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HISTOLOGY; KIDNEY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; UREA NITROGEN BLOOD LEVEL;

EID: 0037436035     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01305-0     Document Type: Article

References (29)

1. 1 receptors on cisplatin-induced nephrotoxicity in the rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 361:2000;334-338.
2. Baliga R., Zhang Z., Baliga M., Ueda N., Shah S.V. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int. 53:1998;394-401.
3. Chopra S., Kaufman J.S., Jones T.W., Hong W.K., Gehr M.K., Hamburger R.J., Flamenbaum W., Trump B.F. Cis-diamminedichlorplatinum-induced acute renal failure in the rat. Kidney Int. 21:1982;54-64.
4. Chu V.L., Cheng J.W. Fenoldopam in the prevention of contrast media-induced acute renal failure. Ann. Pharmacother. 35:2001;1278-1282.
5. Dobyan D.C., Levi J., Jacobs C., Kosek J., Weiner M.W. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J. Pharmacol. Exp. Ther. 213:1980;551-556.
6. Dobyan D.C., Bull J.M., Strebel F.R., Sunderland B.A., Bulger R.E. Protective effects of O-(beta-hydroxyethyl)-rutoside on cis-platinum-induced acute renal failure in the rat. Lab. Invest. 55:1986;557-563.
7. Elferink F., van der Vijgh W.J., Klein I., Pinedo H.M. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. Clin. Chem. 32:1986;641-645.
8. Heidemann H.T., Gerkens J.F., Jackson E.K., Branch R.A. Attenuation of cisplatinum-induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide. Naunyn-Schmiedeberg's Arch. Pharmacol. 329:1985;201-205.
9. Jones T.W., Chopra S., Kaufman J.S., Flamenbaum W., Trump B.F. Cis-diamminedichloroplatinum (II)-induced acute renal failure in the rat. Correlation of structural and functional alterations. Lab. Invest. 52:1985;363-374.
10. Kato K., Terao S., Shimamoto N., Hirata M. Studies on scavengers of active oxygen species: 1. Synthesis and biological activity of 2-O-alkylascorbic acids. J. Med. Chem. 31:1988;793-798.
11. Kuriyama H., Waki M., Nakagawa M., Tsuda M. Involvement of oxygen free radicals in experimental retinal ischemia and the selective vulnerability of retinal damage. Ophthalmic Res. 33:2001;196-202.
12. Kuzuya T., Hoshida S., Nishida M., Kim Y., Fuji H., Kitabatake A., Kamada T., Tada M. Role of free radicals and neutrophils in canine myocardial reperfusion injury: myocardial salvage by a novel free radical scavenger, 2-octadecylascorbic acid. Cardiovasc. Res. 23:1989;323-330.
13. Madias N.E., Harrington J.T. Platinum nephrotoxicity. Am. J. Med. 65:1978;307-314.
14. Matsushima H., Yonemura K., Ohishi K., Hishida A. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J. Lab. Clin. Med. 131:1998;518-526.
15. Miyaji T., Kato A., Yasuda H., Fujigaki Y., Hishida A. Role of the increase in p21 in cisplatin-induced acute renal failure in rats. J. Am. Soc. Nephrol. 12:2001;900-908.
16. Rao M., Kumar M.M., Rao M.A. In vitro and in vivo effects of phenolic antioxidants against cisplatin-induced nephrotoxicity. J. Biochem. 125:1999;383-390.
17. Saad S.Y., Najjar T.A., Al-Sohaibani M.O. The effect of rebamipide on cisplatin-induced nephrotoxicity in rats. Pharmacol. Res. 42:2000;81-86.
18. Sugihara K., Gemba M. Modification of cisplatin toxicity by antioxidants. Jpn. J. Pharmacol. 40:1986;353-355.
19. Sugihara K., Nakano S., Koda M., Tanaka K., Fukuishi N., Gemba M. Stimulatory effect of cisplatin on production of lipid peroxidation in renal tissues. Jpn. J. Pharmacol. 43:1987;247-252.
20. Tumlin J.A., Wang A., Murray P.T., Mathur V.S. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am. Heart J. 143:2002;894-903.
21. A dopamine receptors with G proteins in proximal tubules of the spontaneously hypertensive rat. J. Hypertens. 16:1998;1307-1313.
22. 1 receptors in renal proximal tubules from normotensive rat and SHR. Am. J. Physiol. 268:1995;F1009-F1016.
23. Weiner M.W., Jacobs C. Mechanism of cisplatin nephrotoxicity. Fed. Proc. 42:1983;2974-2978.
24. Winston J.A., Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am. J. Physiol. 249:1985;F490-F496.
25. 1-like receptors. Circulation. 101:2000;2038-2302.
26. 1 receptor agonist, in anesthetized dogs. Eur. J. Pharmacol. 322:1997;45-53.
27. 1 receptor agonist, in anesthetized dogs. J. Cardiovasc. Pharmacol. 29:1997;382-388.
28. 1 receptor agonist activity of YM435 in the canine renal vasculature. Gen. Pharmacol. 29:1997;229-232.
29. 1 receptor agonist, in a canine model of ischemic acute renal failure. Gen. Pharmacol. 31:1998;803-807.